Clinical Trials Logo

Filter by:
NCT ID: NCT06214754 Completed - Clinical trials for Patients With Atherosclerotic Plaques in the Coronary Arteries That Require Excision

Efficacy and Safety of Intravascular High-pressure Cutting Balloon Catheters for PCI

Start date: June 16, 2023
Phase: N/A
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of intravascular high-pressure cut balloon catheter compared to cut balloon catheter during PCI, and to support product registration and clinical application.

NCT ID: NCT06214741 Recruiting - Obesity Clinical Trials

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Start date: January 15, 2024
Phase: Phase 3
Study type: Interventional

This study in China is open to adults who are at least 18 years old who are living with overweight or obesity. People with a body mass index (BMI) of 28 kg/m^2 or higher or 24 kg/m^2 or higher with at least 1 weight related problem can join the study. The main purpose of this study is to find out whether a medicine called survodutide helps people with overweight or obesity. 2 different doses of survodutide are tested in this study. Participants are put into 3 groups by chance. Each participant has an equal chance of being in each group. 2 groups get different doses of survodutide. 1 group gets placebo. Participants get survodutide or placebo as injections under the skin once a week for about 19 months. Placebo injections look like survodutide injections but do not contain any medicine. Participants are in the study for about 21 months. During this time, there are 20 visits. 14 visits are in person at the study site. Where possible, 6 visits can be done by video call, or by phone in rare cases. During this time, doctors regularly measure participant's body weight. Results are compared between the survodutide groups and placebo group to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

NCT ID: NCT06214481 Completed - Atopic Dermatitis Clinical Trials

A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants

Start date: January 23, 2024
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the pharmacokinetics of rocatinlimab after single subcutaneous (SC) administration in healthy Chinese participants.

NCT ID: NCT06214247 Completed - Clinical trials for Coronary Artery Disease

Wedge NC - Scoring Balloon Dilatation Catheter

Start date: August 27, 2021
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of Wedge NC Scoring Balloon Dilatation Catheter for dilating coronary stenosis during PCI in comparison with a similar product on the market.

NCT ID: NCT06214195 Recruiting - Clinical trials for Cardiotoxicity Induced by Drug Therapy for Breast Cancer

The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity

START
Start date: January 20, 2024
Phase: Phase 3
Study type: Interventional

To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.

NCT ID: NCT06214182 Enrolling by invitation - Clinical trials for Ventricular Septal Defect

Immune Heterogeneity Before and After Cardiopulmonary Bypass in Children

Start date: January 1, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about functional heterogeneity of immune cells before and after cardiopulmonary bypass (CPB) in children with congenital heart disease (CHD). The main question[s] it aims to answer are: - Does CPB cause immune paralysis after CHD surgery? - How does the functional heterogeneity of immune cells change before and after CPB in children undergoing CHD surgery? Participants will receive 3ml of peripheral blood before CPB, 2 hours after CPB, and 3 days after CPB, and the peripheral blood samples will be sequenced by single cell to explore the immune heterogeneity before and after CPB.

NCT ID: NCT06214156 Recruiting - Advanced Melanoma Clinical Trials

A Clinical Study of T3011 in Subjects With Advanced Melanoma

Start date: January 26, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.

NCT ID: NCT06214143 Recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Start date: January 11, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors

NCT ID: NCT06214117 Not yet recruiting - Emergence Delirium Clinical Trials

Comparison of Emergence Delirium: Remimazolam vs Sevoflurane Anesthesia

CEDCRSA
Start date: February 2024
Phase: Phase 4
Study type: Interventional

Emergence delirium can lead to a range of clinical problems and is even associated with short-term behavioral changes in children. Pediatric ear, nose, and throat (ENT) surgery is one of the most common surgical types for postoperative delirium in children. Sevoflurane anesthesia is also a known cause of postoperative delirium. Therefore, this study aims to explore whether there is a difference in the incidence of postoperative delirium in children under remimazolam general anesthesia and sevoflurane anesthesia.

NCT ID: NCT06214078 Recruiting - Clinical trials for Ulcerative Colitis Chronic Mild

Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the safety and efficacy of nicotinamide mononucleotide (NMN) and placebo in patients with mild ulcerative colitis (UC). The main question it aims to answer is Whether NMN can alleviate the intestinal pathology of UC patients, so as to play a role in UC treatment or adjuvant therapy. Participants will be randomized into two groups, an NMN group or a placebo group. Patients in the NMN group were treated with NMN intervention for 8 weeks. The placebo group received a placebo intervention for 8 weeks.